Spots Global Cancer Trial Database for YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma
Official Title: An Exploratory Clinical Study on the Safety and Efficacy of YTS104 Cell Injection in the Treatment of Relapsed or Refractory Multiple Myeloma
Study ID: NCT05913804
Conditions
Interventions
Study Description
Brief Summary: This is a single-center, single-arm, open-label phase I clinical study to determine the safety and efficacy of relapsed or refractory multiple myeloma subjects
Detailed Description: This study will recruit LILRB4 positive multiple myeloma subjects,and Subjects should undergo FC chemotherapy before returning the cells, then followed by infusion of YTS104 cells injection. YTS104 cells injection will be intravenously infused with a escalated dose of 1E6#3E6#6E6#1E7 cells/kg.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Contact Details
Name: Gang An
Affiliation: Institute of Hematology & Blood Diseases Hospital Ethics Committee
Role: STUDY_DIRECTOR
Name: Lugui Qiu
Affiliation: Institute of Hematology & Blood Diseases Hospital Ethics Committee
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
